5WK0.F Aligos Therapeutics, Inc.

Healthcare Biotechnology Frankfurt Exchange
2.52 EUR
Close of Nov 12, 2026
2.20 11.10
Market cap
EUR 13.7M
P/E
-
P/B
2.05x
ROE
-547.2%
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.

Is 5WK0.F undervalued?

Graham number

The Graham number of Aligos Therapeutics, Inc. cannot be estimated reliably (it needs positive earnings and book value).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

Aligos Therapeutics, Inc. fundamental analysis

No fundamental analysis for Aligos Therapeutics, Inc. yet.

Aligos Therapeutics, Inc. stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About Aligos Therapeutics, Inc.

Aligos Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapeutics to address unmet medical needs in liver and viral diseases. Its drug candidate, ALG-055009, a small molecule THR-ß agonist that is in the Phase 2a clinical trial for the treatment of metabolic dysfunction-associated steatohepatitis and obesity. The company also develops pevifoscorvir sodium, a capsid assembly modulator, which is in Phase 2 B clinical trial;…

Full company profile